Alzheimer's disease
Conditions
Interventions
Experimental group:Bushenyisui formulas
Control group:Hydrochloride donepezil
Sponsors
The second hospital affiliated toTianjin university of traditional Chinese medicine
Eligibility
Sex/Gender
All
Age
60 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Accord with dementia and alzheimer's disease diagnosis standard (the DSM-IV standard); 2. TCM syndrome diagnostic for kindney-essence insufficient; 3. Aged 60 to 85 years old; 4. HIS <=4 points; 5. HAMD <=7 points; 6. Subjects and/or its guardian informed agreement signed; 7. CDR=1.0.
Exclusion criteria
Exclusion criteria: 1. People with vascular dementia or other causes of dementia caused by one; 2. With severe heart, liver, kidney and hematopoietic system disease (Sinus bradycardia and conduction blockAspertate aminotransferaseCereal third transaminase More than 2 times of the normal cap; Urea nitrogen more than 1.5 times the normal capThe serum creatinine more than normal range); 3. Allergic constitution or Donepezil HClpiperidine derivatives allergies; 4. Nearly a month may influence the use of any history of drug of cognitive function; 5. The drug therapy failed to control high blood pressure (Systolic blood pressure is greater than 180 mmHg or Diastolic pressure is higher than 100 mmHg); 6. be provided with diseases which Interference cognitive tests, such as aphasiahemiplegia and others(Severe hearing, vision defectsthe difficulty of Verbal communication, eg.); 7. A history of syncope, asthma history and history of chronic obstructive pulmonary disease; 8. Taking part in other drugs in clinical subject; 9. Critical illnessHard to study the efficacy and safety of the drug to make exact evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood routine test;Urine routine test;stool routine test;glutamic-oxalacetic transaminase;ALT;BUN;adrenocorticotrophic hormone;Plasma cortisol;growth hormone;estradiol;testosterone;catecholamine;acetylcholine;vasoactive intestinal peptide VIP;thyrotropin;Cr;Interleukin - 1; | — |
Secondary
| Measure | Time frame |
|---|---|
| Interleukin - 2;garma interferon;T Lymphocyte subsets;Total Tau protein;Phosphorylated Tau protein;Beta Amyloid protein 1-42;transforming growth factor; | — |
Countries
China
Contacts
Public ContactYulian Zhang
Outcome results
None listed